ReproNovo公司为治疗男性不孕症和妇女生殖问题的临床试验提供了65M美元。 ReproNovo secures $65M for clinical trials of treatments for male infertility and women’s reproductive issues.

Repronovo是一家为生殖健康问题进行治疗的公司,它在其他保健投资者的支持下,获得了由Jeito Capital牵头的6 500万美元资金。 ReproNovo, a company developing treatments for reproductive health issues, has secured $65 million in funding led by Jeito Capital, with support from other healthcare investors. 这些资金将推进针对男性不育症的RPN-001和针对失明和胚胎植入问题的RPN-002第二阶段临床试验。 The funds will advance Phase 2 clinical trials for RPN-001, aimed at male infertility, and RPN-002, targeting adenomyosis and embryo implantation issues. 这项投资针对不孕症方面的全球健康挑战,旨在改善妇女健康成果。 This investment targets global health challenges in infertility and aims to improve women's health outcomes.